Can JAK Inhibitors Save Lives From COVID-19? Pfizer Might Let RECOVERY Answer The Question
Promising Signs From Phase II Study
Pfizer has unveiled promising results from a study of Xeljanz but needs a bigger trial. Given RECOVERY’s track record, the pharma company may opt to wait for its results.
You may also be interested in...
Lilly signs licensing pacts with Cipla, Sun and Lupin for baricitinib in COVID-19, with possibly more in store. But will challenger Natco, which has apparently already rolled out its cut-price version of the JAK inhibitor, change tack amid the Indian government's mixed position on compulsory licensing issues in an ongoing court case?
Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.
Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker